Navigation Links
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
Date:2/17/2011

SAN FRANCISCO, Feb. 17, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2010 on Tuesday, March 1, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Tuesday, March 29, 2011. To access the conference call, follow these instructions:Dial: (866) 713-8307 (U.S.); (617) 597-5307 (international)Passcode: 79375407 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Tuesday, March 29, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 10590598.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 late-stage development program to treat opioid-induced constipation and its NKTR-119 earlier stage development program for the treatment of pain without constipation side effects.  NKTR-181 is a novel mu-opioid analgesic molecule that is being prepared for Phase 1 clinical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585, jruddock@nektar.com


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- , , Marks E-QURE , ... distribution agreement, following similar agreements in Israel and ... 5 billion global market ... a leader in medical devices for the treatment of advanced wound care, announced ... (TeckMedica) in Colombia for the Company,s patented Bio-electrical Signal ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 The ... 1,669.40 billion by 2021 from USD 1,179.20 billion in ... period. Increasing prevalence of chronic diseases, increasing demand ... the factors driving the growth of this market. Whereas, ... and generic drugs offer significant growth opportunities for players ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a ... sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, ...
(Date:1/19/2017)... Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... hazards while driving during a rain storm by slowing down and increasing the space ... on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics ... simplify the editing process for all media productions," said Christina Austin - CEO ... 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... Calif, USA; and SHANGHAI, China – , ... ... 2017 -- Global public health organization NSF International has certified ... arsenic) to NSF/ANSI 53: Drinking Water Treatment Units – Health ... This certification verifies that MicroCeramics’ NanoNose Pitcher Filter System filters ...
Breaking Medicine News(10 mins):